- Home
- DHR vs BMY Comparison
DHR vs BMY Comparison
Compare DHR & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DHR | BMY |
|---|---|---|
| Founded | 1969 | 1887 |
| Country | United States | United States |
| Employees | N/A | 32500 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.6B | 115.3B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | DHR | BMY |
|---|---|---|
| Price | $180.05 | $56.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 15 |
| Target Price | ★ $241.69 | $61.73 |
| AVG Volume (30 Days) | 4.4M | ★ 8.9M |
| Earning Date | 04-21-2026 | 04-30-2026 |
| Dividend Yield | 0.89% | ★ 4.38% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.45 | N/A |
| Revenue | ★ $19,893,000,000.00 | N/A |
| Revenue This Year | $5.43 | N/A |
| Revenue Next Year | $5.74 | N/A |
| P/E Ratio | $119.34 | ★ $17.26 |
| Revenue Growth | ★ 8.53 | N/A |
| 52 Week Low | $160.93 | $42.52 |
| 52 Week High | $242.80 | $62.89 |
Technical Indicators
Market Signals| Indicator | DHR | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 57.40 | 44.26 |
| Support Level | $178.68 | $55.93 |
| Resistance Level | $198.50 | $57.04 |
| Average True Range (ATR) | 5.00 | 1.28 |
| MACD | 1.94 | 0.10 |
| Stochastic Oscillator | 98.86 | 30.75 |
Price Performance
Historical ComparisonAbout DHR Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.